1
MAGNIER EMMANUEL , GONCALVES ANNE MARIE , BOUVET SEBASTIEN , ETCHEBERRY ARNAUD , PEGOT BRUCE , SENGMANY STEPHANE : [fr] PROCEDE ET REACTEUR DELECTRO-REDUCTION DU GAZ SF6. CENTRE NAT DE LA RECH SCIENT, UNIV PARIS VAL DE MARNE , UNIV DE VERSAILLES ST QUENTIN EN YVELINES , May 5, 2017: FR3043095-A1

[fr] La présente invention concerne un procédé d'électro-réduction de gaz d'hexafluorure de soufre (SF6), caractérisé en ce qu'il implique la mise en œuvre des étapes suivantes : a) introduction du gaz SF6 dans un réacteur d'électro-réduction contenant un sel de fond et un solvant anhydre dudit gaz ...


2
Wilson George S, Bindra Dilbir S, Hill Brian S, Thevenot Daniel R, Sternberg Robert, Reach Gerard Md, Zhang Yanan: Implantable glucose sensor.. Univ Kansas, Univ Paris Val de Marne, Inst Nat Sante Rech Med, February 3, 1993: EP0525127-A1

Implantable enzymatic sensors (25, 43, 44) for biochemicals such as glucose are provided having an ideal size and geometry for optional long term implantation and linear responses over the concentration ranges of interest. The sensors (25, 43, 44) include an elongated body (10, 26, 46) supporting an ...


3
RENARD ESTELLE , MANGEON CARINE , LANGLOIS VALERIE : [fr] FONCTIONNALISATION DE FIBRES LIGNO-CELLULOSIQUES PAR THIOLENE PAR VOIE PHOTOCHIMIQUE. CENTRE NAT DE LA RECH SCIENT, UNIV PARIS VAL DE MARNE , September 2, 2016: FR3033173-A1

[fr] La présente invention concerne un procédé de fonctionnalisation d'une fibre végétale ligno-cellulosique et de préparation d'un renfort pour la conception d'un matériau composite (A) comprenant ladite fibre végétale ligno-cellulosique fonctionnalisée, comprenant les étapes de : (a1) mise en cont ...


4
Barritault Denis Stephen Charl, Caruelle Jean Pierre, Caruelle Lebris Daniele Jeanne, Chopin Dominique Khiem Marie, Voisin Marie Catherine Paule G: Process for assaying the fgf acid form in fluids or biological tissues and applications thereof.. Univ Paris Val de Marne, September 4, 1991: EP0444102-A1

A sample of fluid or biological tissue is assayed to determine the quantity of the aFGF form it may contain, whereby the aFGF quantity defined in this way constitutes a representative value of the pathological condition. Application in particular in cancerology.


5
Barritault Denis, Caruelle Jean Pierre, Aamiri Ahmed, Gautron Jean: Use of substituted dextrane for treating nervous system damage, and heparane sulphate-enriched fractions. Univ Paris Val de Marne, January 15, 1997: EP0752865-A1

The use of at least one polymer or biopolymer known as HBGFPP, capable of specifically protecting growth factors of families FGF and beta-TGF from trypsin damage, for preparing a drug for treating nervous system damage, is disclosed.


6
Barritault Denis, Caruelle Jean Pierre, Desgranges Pascal, Gautron Jean, Meddahi Anne: Use of biopolymers for the muscle treatment. Univ Paris Val de Marne, January 15, 1997: EP0752862-A1

The use of at least one polymer or biopolymer known as HBGFPP, capable of specifically protecting growth factors of families FGF and beta-TGF from trypsin damage, for preparing a drug for treating muscle tissue, is disclosed.


7
Barritault Denis, Caruelle Jean Pierre, Meddahi Anne: Use of biopolymers for digestive tract injuries treatment. Univ Paris Val de Marne, January 15, 1997: EP0752863-A1

The use of at least one polymer or biopolymer known as HBGFPP, capable of specifically protecting growth factors of families FGF and beta-TGF from trypsin damage, for preparing a drug for treating injuries to the digestive tract and the primary or secondary derived tissues of the entoderm and mesode ...


8
Barritault Denis, Caruelle Jean Pierre, Hornebeck William, Meddahi Anne: Use of growth factor protecting polymers for treating inflammation. Univ Paris Val de Marne, January 15, 1997: EP0752864-A1

The use of at least one polymer or biopolymer known as HBGFPP, which is capable of specifically protecting growth factors of families FGF and beta-TGF from trypsin damage, and does not significantly inhibit coagulation, for preparing a drug for treating inflammation, is disclosed.


9
Barritault Denis, Courty Jose, Laaroubi Khalid: Harp family growth factors, preparation methods therefor and uses thereof. Univ Paris Val de Marne, December 13, 1995: EP0686194-A1

A peptide having a similar sequence to peptide HARP and a mass of 18 kD. The N-terminal end of said peptide has one of the following sequences: NH2-ALA-GLU-ALA-GLY-LYS-LYS-GLU-LYS-PRO-GLU-LYS-LYS; NH2-ALA-VAL-ASP-THR-ALA-GLU-ALA-GLY-LYS-LYS-GLU-LYS-PRO-GLU; LYS-LYS. Said peptide or fragments thereof ...


10